Tissue | Expression Dynamics | Abbreviation |
Colorectum (GSE201348) | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Colorectum/Becker/MYO9A_pca_on_diff_genes.png) | FAP: Familial adenomatous polyposis |
CRC: Colorectal cancer |
Colorectum (HTA11) | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Colorectum/Chen/MYO9A_pca_on_diff_genes.png) | AD: Adenomas |
SER: Sessile serrated lesions |
MSI-H: Microsatellite-high colorectal cancer |
MSS: Microsatellite stable colorectal cancer |
Endometrium | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Endometrium/MYO9A_pca_on_diff_genes.png) | AEH: Atypical endometrial hyperplasia |
EEC: Endometrioid Cancer |
Esophagus | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Esophagus/MYO9A_pca_on_diff_genes.png) | ESCC: Esophageal squamous cell carcinoma |
HGIN: High-grade intraepithelial neoplasias |
LGIN: Low-grade intraepithelial neoplasias |
Lung | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Lung/MYO9A_pca_on_diff_genes.png) | AAH: Atypical adenomatous hyperplasia |
AIS: Adenocarcinoma in situ |
IAC: Invasive lung adenocarcinoma |
MIA: Minimally invasive adenocarcinoma |
Prostate | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Prostate/MYO9A_pca_on_diff_genes.png) | BPH: Benign Prostatic Hyperplasia |
Thyroid | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Thyroid/MYO9A_pca_on_diff_genes.png) | ATC: Anaplastic thyroid cancer |
HT: Hashimoto's thyroiditis |
PTC: Papillary thyroid cancer |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:00451973 | Colorectum | FAP | establishment or maintenance of epithelial cell apical/basal polarity | 14/2622 | 44/18723 | 1.99e-03 | 1.67e-02 | 14 |
GO:00350883 | Colorectum | FAP | establishment or maintenance of apical/basal cell polarity | 15/2622 | 49/18723 | 2.15e-03 | 1.77e-02 | 15 |
GO:00612453 | Colorectum | FAP | establishment or maintenance of bipolar cell polarity | 15/2622 | 49/18723 | 2.15e-03 | 1.77e-02 | 15 |
GO:00901622 | Colorectum | FAP | establishment of epithelial cell polarity | 11/2622 | 31/18723 | 2.26e-03 | 1.84e-02 | 11 |
GO:00308591 | Colorectum | FAP | polarized epithelial cell differentiation | 9/2622 | 24/18723 | 3.66e-03 | 2.60e-02 | 9 |
GO:00017381 | Colorectum | FAP | morphogenesis of a polarized epithelium | 23/2622 | 94/18723 | 4.64e-03 | 3.14e-02 | 23 |
GO:00226045 | Colorectum | CRC | regulation of cell morphogenesis | 74/2078 | 309/18723 | 9.25e-11 | 5.04e-08 | 74 |
GO:00071634 | Colorectum | CRC | establishment or maintenance of cell polarity | 57/2078 | 218/18723 | 3.96e-10 | 1.58e-07 | 57 |
GO:00510563 | Colorectum | CRC | regulation of small GTPase mediated signal transduction | 69/2078 | 302/18723 | 3.34e-09 | 9.08e-07 | 69 |
GO:00300104 | Colorectum | CRC | establishment of cell polarity | 40/2078 | 143/18723 | 2.09e-08 | 3.23e-06 | 40 |
GO:00343294 | Colorectum | CRC | cell junction assembly | 83/2078 | 420/18723 | 1.08e-07 | 1.29e-05 | 83 |
GO:00430874 | Colorectum | CRC | regulation of GTPase activity | 69/2078 | 348/18723 | 1.11e-06 | 6.69e-05 | 69 |
GO:00435473 | Colorectum | CRC | positive regulation of GTPase activity | 49/2078 | 255/18723 | 8.67e-05 | 1.77e-03 | 49 |
GO:00901623 | Colorectum | CRC | establishment of epithelial cell polarity | 10/2078 | 31/18723 | 1.37e-03 | 1.50e-02 | 10 |
GO:00350884 | Colorectum | CRC | establishment or maintenance of apical/basal cell polarity | 13/2078 | 49/18723 | 2.10e-03 | 2.08e-02 | 13 |
GO:00612454 | Colorectum | CRC | establishment or maintenance of bipolar cell polarity | 13/2078 | 49/18723 | 2.10e-03 | 2.08e-02 | 13 |
GO:00451974 | Colorectum | CRC | establishment or maintenance of epithelial cell apical/basal polarity | 12/2078 | 44/18723 | 2.39e-03 | 2.29e-02 | 12 |
GO:00308592 | Colorectum | CRC | polarized epithelial cell differentiation | 8/2078 | 24/18723 | 3.25e-03 | 2.81e-02 | 8 |
GO:002260415 | Endometrium | AEH | regulation of cell morphogenesis | 79/2100 | 309/18723 | 1.04e-12 | 2.24e-10 | 79 |
GO:000716310 | Endometrium | AEH | establishment or maintenance of cell polarity | 54/2100 | 218/18723 | 1.30e-08 | 8.47e-07 | 54 |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
MYO9A | SNV | Missense_Mutation | | c.6722A>T | p.Glu2241Val | p.E2241V | B2RTY4 | protein_coding | deleterious(0) | benign(0.36) | TCGA-A2-A0EY-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | adriamycin | SD |
MYO9A | SNV | Missense_Mutation | | c.4825G>A | p.Gly1609Arg | p.G1609R | B2RTY4 | protein_coding | tolerated_low_confidence(0.22) | possibly_damaging(0.541) | TCGA-A8-A09Z-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
MYO9A | SNV | Missense_Mutation | novel | c.658N>A | p.Asp220Asn | p.D220N | B2RTY4 | protein_coding | deleterious(0) | probably_damaging(0.995) | TCGA-AC-A3BB-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | cytoxan | CR |
MYO9A | SNV | Missense_Mutation | rs764262772 | c.500G>A | p.Arg167Gln | p.R167Q | B2RTY4 | protein_coding | deleterious(0.01) | possibly_damaging(0.808) | TCGA-AN-A046-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
MYO9A | SNV | Missense_Mutation | rs144500644 | c.5761N>T | p.Arg1921Trp | p.R1921W | B2RTY4 | protein_coding | deleterious(0.02) | probably_damaging(0.999) | TCGA-AN-A0FY-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
MYO9A | SNV | Missense_Mutation | novel | c.2983N>G | p.Gln995Glu | p.Q995E | B2RTY4 | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-BH-A0B6-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
MYO9A | SNV | Missense_Mutation | | c.424N>G | p.Gln142Glu | p.Q142E | B2RTY4 | protein_coding | tolerated(0.07) | benign(0.159) | TCGA-BH-A0BL-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | adriamycin | CR |
MYO9A | SNV | Missense_Mutation | | c.3359N>C | p.Ile1120Thr | p.I1120T | B2RTY4 | protein_coding | tolerated(0.85) | benign(0) | TCGA-BH-A18I-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | taxotere | CR |
MYO9A | SNV | Missense_Mutation | rs757005328 | c.6257N>C | p.Ile2086Thr | p.I2086T | B2RTY4 | protein_coding | deleterious(0) | probably_damaging(0.998) | TCGA-D8-A1XK-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicine+cyclophosphamide | SD |
MYO9A | SNV | Missense_Mutation | | c.6118N>C | p.Cys2040Arg | p.C2040R | B2RTY4 | protein_coding | deleterious(0) | probably_damaging(0.997) | TCGA-D8-A1XK-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicine+cyclophosphamide | SD |